down arrow

Annovis Bio, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US03615A1088
USD
3.65
-0.02 (-0.54%)

Dec 19

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

3.463.74

52 Week

1.115.60
Valuation
Technical
Day's Volume

CASH

873.64 k

Shareholding (Mar 2025)

FII

1.32%

Held by 16 FIIs

DII

94.33%

Held by 5 DIIs

Promoter

0.00%

How big is Annovis Bio, Inc.?

22-Jun-2025

As of Jun 18, Annovis Bio, Inc. has a market capitalization of 51.25 million, with net sales of 0.00 million and a net profit of -29.06 million over the latest four quarters. As of Dec'24, shareholder's funds were 9.31 million and total assets were 13.93 million.

Market Cap: As of Jun 18, Annovis Bio, Inc. has a market capitalization of 51.25 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Annovis Bio, Inc. reported net sales of 0.00 million and a net profit of -29.06 million.<BR><BR>Balance Sheet Snapshot: As of Dec'24, the company's shareholder's funds amounted to 9.31 million, while total assets were reported at 13.93 million.

Read More

What does Annovis Bio, Inc. do?

22-Jun-2025

Annovis Bio, Inc. is a clinical stage pharmaceutical company focused on developing treatments for neurodegenerative diseases like Alzheimer's and Parkinson's. As of March 2025, it has a market cap of $51.25 million and reported a net profit loss of $6 million.

Overview: <BR>Annovis Bio, Inc. is a clinical stage, drug platform company focused on addressing neurodegeneration, such as Alzheimer's disease and Parkinson's disease, within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -6 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 51.25 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.92 <BR>Return on Equity: -110.36% <BR>Price to Book: 2.13<BR><BR>Contact Details: <BR>Address: 1055 Westlakes Dr Ste 300, BERWYN PA: 19312-2410 <BR>Tel: 1 610 7273913 <BR>Fax: 1 610 7274001 <BR>Website: https://www.annovisbio.com/

Read More

Who are in the management team of Annovis Bio, Inc.?

22-Jun-2025

As of March 2022, the management team of Annovis Bio, Inc. includes Chairman Mr. Michael Hoffman and Executive Board Member Dr. Maria Maccecchini, along with Board Members Dr. Claudine Bruck, Mr. Robert Whelan, and Mr. Mark White.

As of March 2022, the management team of Annovis Bio, Inc. includes Mr. Michael Hoffman, who serves as the Chairman of the Board, and Dr. Maria Maccecchini, who is an Executive Board Member. Additionally, the Board of Directors comprises Dr. Claudine Bruck, Mr. Robert Whelan, and Mr. Mark White, who are all Board Members.

Read More

Is Annovis Bio, Inc. technically bullish or bearish?

20-Sep-2025

As of September 11, 2025, Annovis Bio, Inc. shows a mildly bearish trend with mixed signals from technical indicators, significantly underperforming the S&P 500 with a year-to-date return of -53.28%.

As of 11 September 2025, the technical trend for Annovis Bio, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a bearish daily moving average and a weekly MACD that is mildly bullish, indicating mixed signals. The Bollinger Bands are bearish on the weekly and mildly bearish on the monthly, while the KST shows a mildly bearish weekly trend and a bearish monthly trend. Additionally, there is no trend indicated by Dow Theory or OBV. <BR><BR>In terms of performance, the stock has significantly underperformed the S&P 500 across all periods, with a year-to-date return of -53.28% compared to the S&P 500's 12.22%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 46 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.93

stock-summary
Return on Equity

-128.44%

stock-summary
Price to Book

2.50

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-6 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
57.33%
0%
57.33%
6 Months
35.19%
0%
35.19%
1 Year
-17.05%
0%
-17.05%
2 Years
-67.12%
0%
-67.12%
3 Years
-67.44%
0%
-67.44%
4 Years
-81.8%
0%
-81.8%
5 Years
-40.65%
0%
-40.65%

Annovis Bio, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-229.09%
EBIT to Interest (avg)
-22.48
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.92
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
14.94%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.60
EV to EBIT
-1.60
EV to EBITDA
-1.60
EV to Capital Employed
22.18
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-1384.59%
ROE (Latest)
-110.36%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bearish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 5 Schemes (4.35%)

Foreign Institutions

Held by 16 Foreign Institutions (1.32%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -24.00% vs 47.37% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.30",
          "val2": "-7.80",
          "chgp": "19.23%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "1.30",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.10",
          "val2": "4.10",
          "chgp": "-102.44%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.20",
          "val2": "-5.00",
          "chgp": "-24.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 56.23% vs -122.13% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-26.70",
          "val2": "-45.00",
          "chgp": "40.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.90",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "3.60",
          "val2": "-11.80",
          "chgp": "130.51%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-24.60",
          "val2": "-56.20",
          "chgp": "56.23%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-6.30
-7.80
19.23%
Interest
0.00
1.30
-100.00%
Exceptional Items
-0.10
4.10
-102.44%
Consolidate Net Profit
-6.20
-5.00
-24.00%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -24.00% vs 47.37% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-26.70
-45.00
40.67%
Interest
1.90
0.00
Exceptional Items
3.60
-11.80
130.51%
Consolidate Net Profit
-24.60
-56.20
56.23%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 56.23% vs -122.13% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Annovis Bio, Inc. stock-summary
stock-summary
Annovis Bio, Inc.
Pharmaceuticals & Biotechnology
Annovis Bio, Inc. is a clinical stage, drug platform company. The Company is focused on addressing neurodegeneration, such as Alzheimer's disease in Down syndrome (AD-DS), Alzheimer's disease (AD) and Parkinson's disease (PD). The Company is engaged in developing drugs that normalize the transport of information within and between nerve cells, called axonal transport. Its lead product pipelines are ANVS-401, which include ANVS-401 for AD, ANVS-401 for AD-DS, ANVS-401 for PD; ANVS-405 and ANVS-301. Its ANVS-401 restores axonal transport and homeostasis in the brain by inhibiting the synthesis of neurotoxic proteins. The Company is in an ongoing Phase II A proof-of-concept study in mild to moderate AD patients and a ready program to conduct a second Phase II A study in PD patients. The Company has also developed compound to treat acute neurodegeneration traumatic brain injury (TBI) and stroke.
Company Coordinates stock-summary
Company Details
1055 Westlakes Dr Ste 300 , BERWYN PA : 19312-2410
stock-summary
Tel: 1 610 7273913
stock-summary
https://www.annovisbio.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."